Authors: Barbara Anne Pickut Chris van der Linden Sophie Dethy Hilde Van De Maele Diederik Zegers de Beyl
Publish Date: 2013/12/31
Volume: 35, Issue: 6, Pages: 861-866
Abstract
Data concerning efficacy safety and patient satisfaction of levodopa/carbidopa intestinal gel LCIG Duodopa AbbVie Wavre Belgium infusion in routine clinical practice were needed to maintain reimbursement of the drug in Belgium Patients with advanced Parkinson’s disease in 27 neurology centers across Belgium were included Of 100 patients who underwent nasointestinal NI evaluation with LCIG 67 received permanent treatment with LCIG via percutaneous endoscopic gastrostomy and jejunal tube PEG/J Efficacy was evaluated at baseline on levodopa and during a followup FU visit on LCIG using the Unified Parkinson’s Disease Rating Scale UPDRS IV Patient appraisal of the Duodopa system was evaluated using a visual analog scale for therapy compliance userfriendliness and global appreciation Safety was assessed by reporting suspected adverse drug reactions ADRs and medical devicerelated complaints FU evaluations were conducted in 37 patients Significant improvement at FU was observed for motor complications UPDRS IV as the mean change from baseline to FU was −63 95 CI −81 to −45 Patient appraisal showed high scores for hospital delivery userfriendliness and patient global appreciation as well as family appreciation of the system on daily life Few ADRs and system malfunctions were reported with no unexpected ADRs In conclusion the symptoms and impact of Parkinsonism improved markedly when LCIG PEG/J was initiatedThis Belgian observational study was sponsored by AbbVie sa/nv Wavre Belgium AbbVie contributed to study design research and interpretation of data writing reviewing and approving the publicationThe authors are grateful to all neurologists who participated as investigators in the Belgian Duodopa Study Algoed L Gent Bourgeois Ph Roeselare Bourgeois P Kortrijk Cras P Antwerpen Daems P Oostende Delvaux V Liège De Quick M Tienen Flamez A Brussel Geens K Brasschaat Goethals M Torhout Leenders J Geel Pals Ph Duffel Soeur M Bruxelles Strauven T Wilrijk Tack Ph Tielt Van den Abeele K Waregem Vandenberghe W Leuven Van den kerchove M Antwerpen Van Landegem W Wilrijk Van Zandijcke M Brugge Vercruyssen A Sint Niklaas Verhalle D Oostende Viaene MK Geel Viaene P GenkBarbara Pickut received honoraria from AbbVie and St Jude Medical Chris van der Linden and Sophie Dethy attest that they have no relevant financial disclosures or relationships with people/organizations that may have inappropriately influenced the outcome/results of this study Hilde Van De Maele is an employee of AbbVie SA/NV Wavre Belgium Diederik Zegers de Beyl received honoraria and travel expenses from AbbVie
Keywords: